Stay Informed
Medical Links
- 2010 Alzheimer's Disease Facts and Figures - updated facts for 2010 on AD
- Abbott Laboratories
- Adult Care Advisors
- Alcoeur Gardens - Special care for the Alzheimer’s Disease patient
- Alzheimer’s Disease information provided by Novartis Pharmaceuticals - For patients and caregivers
- Alzheimer’s Foundation of America
- Alzheimer’s Foundation of America - Support resource for patients, cargivers and health care professionals
- Alzheimer’s Disease Clinical Trials
- Bristol-Myers Squibb Prodromal AD study
- CLINICAL RESEARCH TRIALS IN ALZHEIMER'S DISEASE - All current AD trials in the United States
- Clinical Trials at Memory Enhancement Centers of America - Clinical Research Trials
- COVANCE
- Dr Danov : Neuropsychologist PC - Pediatric and Adult Neuropsychology
- Eisai
- Elan Corporation
- Geriatric Medical Center of Dr. Sanjiv, Sharma, MD - First class geriatric medical care for seniors
- ICON Central Laboratories
- Lori Wright Consulting - CNS research consulting firm
- Neuronascent
- Novartis
- Pfizer
- Quintiles
- Sanofi-Aventis
- The Regency at Dover (Toms River, NJ) - “A Premier Senior Club”
- Wyeth Pharmaceuticals
Links
Search
 |
Joel S. Ross, MD |
MD FACP AGSF CMD CPI |
President and Founder |
Memory Enhancement Center |
of America, Inc. |
4 Industrial Way West, 2nd Floor |
Eatontown, New Jersey 07724 |
732.571.1535 |
« What’s the latest with “nutriceuticals” on memory loss? | Home | Even minor memory lapses could be significant!!! »
Will Dimebon be the next FDA approved Drug for AD?
By Joel Ross | January 11, 2010
I have been very actively researching Dimebon in clinical research studies under strict FDA and industry guidelines, and saw the below article and felt my readers would be most interested in learning more about an “outsider” looking in at the potential for this drug if FDA approved for Alzheimer’s Disease.
For the Treatment of Alzheimer’s Disease, Pfizer/Medivation’s Dimebon Will Garner Peak Year Sales of $1.5 Billion
Clinical Trial Results Could Promote the Use of Dimebon Throughout the Course of Alzheimer’s Disease, According to New Findings from Decision Resources
Press Release Source: Decision Resources On Monday January 11, 2010, 8:00 am EST
WALTHAM, Mass., Jan. 11 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation’s Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer’s disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease. As a result, following its expected launch in 2012, Dimebon will garner peak year sales of $1.5 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The Phase III CONTACT clinical trial for patients with moderate-to-severe Alzheimer’s disease will investigate the effect of Dimebon on neuropsychiatric symptoms and activities of daily living in patients who are already receiving a stable dose of donepezil (Eisai/Pfizer’s Aricept, Bracco’s Memac). The Phase III CONSTELLATION clinical trial will investigate slightly different end points: the effect of Dimebon on cognition, memory and activities of daily living in patients already receiving a stable dose of memantine (Merz/Grupo Grunenthal’s Axura/Akatinol, Lundbeck’s Ebixa, Forest Laboratories’ Namenda).
The Pharmacor finding from the topic entitled Alzheimer’s Disease also reveals that, through 2018, robust 11 percent annual growth in the Alzheimer’s disease drug market will be driven by the launch and uptake of new anti-amyloid monoclonal antibodies, most notably Johnson & Johnson/Pfizer’s bapineuzumab and Eli Lilly’s solanezumab.
“Although monoclonal antibodies are expected to offer superior efficacy over other drugs in the market, their uptake will be initially slow following their launches, owing to potential safety concerns,” said Decision Resources Analyst Matthew Winton, Ph.D. “Nevertheless, bapineuzumab and solanezumab will achieve combined sales of nearly $6 billion in 2018.”
Topics: Alzheimer’s Disease, Clinical Research Study, Clinical Research Trials, Clinical Trials, Dementia | No Comments »